Improvements in transcatheter aortic valve implantation outcomes in lower surgical risk patients: a glimpse into the future.

Lange, R; Bleiziffer, S; Mazzitelli, D; Elhmidi, Y; Opitz, A; Krane, M; Deutsch, MA; Ruge, H; Brockmann, G; Voss, B; Schreiber, C; Tassani, P; Piazza, N

doi:10.1016/j.jacc.2011.10.868

2012

Back
Back to start of result list
Permanent link for displayed object

Title:: Improvements in transcatheter aortic valve implantation outcomes in lower surgical risk patients: a glimpse into the future.
Document type:: Comparative Study; Journal Article
Author(s):: Lange, R; Bleiziffer, S; Mazzitelli, D; Elhmidi, Y; Opitz, A; Krane, M; Deutsch, MA; Ruge, H; Brockmann, G; Voss, B; Schreiber, C; Tassani, P; Piazza, N
Abstract:: The purpose of this study was to investigate the evolution of patient selection criteria for transcatheter aortic valve implantation (TAVI) and its impact on clinical outcomes.Anecdotal evidence suggests that patient selection for TAVI is shifting toward lower surgical risk patients. The extent of this shift and its impact on clinical outcomes, however, are currently unknown.We conducted a single-center study that subcategorized TAVI patients into quartiles (Q1 to Q4) defined by enrollment date. These subgroups were subsequently examined for differences in baseline characteristics and 30-day and 6-month mortality rate. The relationship between quartiles and mortality rate was examined using unadjusted and adjusted (for baseline characteristics) Cox proportional hazard models.Each quartile included 105 patients (n = 420). Compared with Q4 patients, Q1 patients had higher logistic EuroSCORES (25.4 ± 16.1% vs. 17.8 ± 12.0%, p < 0.001), higher Society of Thoracic Surgeons scores (7.1 ± 5.5% vs. 4.8 ± 2.6%, p > 0.001), and higher median N-terminal pro-B-type natriuretic peptide levels (3,495 vs. 1,730 ng/dl, p < 0.046). From Q1 to Q4, the crude 30-day and 6-month mortality rate decreased significantly from 11.4% to 3.8% (unadjusted hazard ratio [HR]: 0.33; 95% confidence interval [CI]: 0.11 to 1.01; p = 0.053) and from 23.5% to 12.4% (unadjusted HR: 0.49; 95 CI: 0.25 to 0.95; p = 0.07), respectively. After adjustment for baseline characteristics, there were no significant differences between Q1 and Q4 in 30-day mortality rate (adjusted HR ratio: 0.29; 95% CI: 0.08 to 1.08; p = 0.07) and 6-month mortality rate (HR: 0.67; 95% CI: 0.25 to 1.77; p = 0.42).The results of this study demonstrate an important paradigm shift toward the selection of lower surgical risk patients for TAVI. Significantly better clinical outcomes can be expected in lower than in higher surgical risk patients undergoing TAVI.
Journal title abbreviation:: J Am Coll Cardiol
Year:: 2012
Journal volume:: 59
Journal issue:: 3
Pages contribution:: 280-7
Language:: eng
Fulltext / DOI:: doi:10.1016/j.jacc.2011.10.868
Pubmed ID:: http://view.ncbi.nlm.nih.gov/pubmed/22196885
Print-ISSN:: 0735-1097
TUM Institution:: Fachgebiet Kardioanästhesie (Prof. Tassani-Prell); Klinik für Herz- und Gefäßchirurgie (Prof. Lange)
BibTeX

Occurrences:

mediaTUM Gesamtbestand Einrichtungen Schools TUM School of Medicine and Health Departments Clinical Medicine Lehr- und Forschungskooperationen mit den Kliniken und Instituten am Deutschen Herzzentrum Institut für Anästhesiologie (DHM) (Prof. Tassani-Prell)Professur für Kardioanästhesie (Prof. Tassani-Prell)2012

mediaTUM Gesamtbestand Einrichtungen Schools TUM School of Medicine and Health Departments Clinical Medicine Lehr- und Forschungskooperationen mit den Kliniken und Instituten am Deutschen Herzzentrum Klinik für Herz- und Gefäßchirurgie (DHM) (Prof. Krane)2012